On Nov. 26, 2019, ChemoCentryx issued a press release announcing that the Advocate trial met both of its primary endpoints, saying Tavneos showed noninferiority of disease remission at 26 weeks and ...

Sarepta Therapeutics failed to win the European drug regulator's backing for its muscle disorder gene therapy on Friday, as ...

Welcome to our live blog tracking the latest news and developments from the United States. Stay updated with real-time ...

Gummies, vapes, drinks and few regulations. Here's what to know about the ingredients that get you high as Texas lawmakers ...